The Effect of a Loading Dose Regimen in the Switch to Brolucizumab for Patients with Aflibercept-Resistant nAMD

Table 1

Clinical characteristics of nAMD patients who switched to brolucizumab with and without the loading dose regimen.

	Loading group (n = 13)	Nonloading group (n = 13)
Age (years), mean (SD)	77.2 (7.2)	79.1 (7.3)	0.55
Sex (female), no. (%)	3 (23.1)	4 (30.8)	0.66
Hypertension, no. (%)	5 (38.5)	4 (30.8)	0.68
Diabetes, no. (%)	3 (23.1)	2 (15.4)	0.62
Smoking habits (ever-smokers), no. (%)	8 (61.5)	10 (76.9)	0.39
AMD subtype, no. (%)			0.42
Typical AMD	3 (23.1)	4 (30.8)
PCV	10 (76.9)	8 (61.5)
RAP	0 (0.0)	1 (7.7)
Follow-up period (mo.), mean (SD)	40.9 (22.2)	56.4 (49.0)	0.98
Total injections (no.), mean (SD)	29.1 (21.0)	28.7 (25.8)	0.84
History of receiving PDT, no. (%)	4 (30.8)	3 (23.1)	0.66